Abstract: The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.

Abstract: The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.

Abstract: The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.

Abstract: Isolated and purified envelope protein of HTLV-I is provided devoid of non-envelope protein of HTLV-I and having substantially the same conformation as the envelope protein in native HTLV-I. The protein is produced recombinantly using a dual vaccinia/T7 polymerase system. Non-glycosylated and glycosylated forms of the protein are produced. Glycosylated forms are recognized by antibodies specific for the envelope protein of HTLV-I. Monoclonal antibodies are provided which are specific for the HTLV-I envelope protein and non-binding to HTLV-I envelope protein in denatured form. The HTLV-I envelope protein is cross-reactive with antibodies of HTLV-II and STLV. The envelope protein is useful in diagnosis of infection by HTLV-I and HTLV-II.

Abstract: Isolated and purified envelope protein of HTLV-I is provided devoid of non-envelope protein of HTLV-I and having substantially the same conformation as the envelope protein in native HTLV-I. The protein is produced recombinantly using a dual vaccinia/T7 polymerase system. Non-glycosylated and glycosylated forms of the protein are produced. Glycosylated forms are recognized by antibodies specific for the envelope protein of HTLV-I. Monoclonal antibodies are provided which are specific for the HTLV-I envelope protein and non-binding to HTLV-I envelope protein in denatured form. The HTLV-I envelope protein is cross-reactive with antibodies of HTLV-II and STLV. The envelope protein is useful in diagnosis of infection by HTLV-I and HTLV-II.